Clin Mol Hepatol.
2025 Apr;31(2):e232-e233. 10.3350/cmh.2025.0203.
Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Affiliations
-
- 1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
- 2Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan
- 3Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan
- 4Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu, Taiwan
- KMID: 2567038
- DOI: http://doi.org/10.3350/cmh.2025.0203
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C
- 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: What's New?
- Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
